Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma · line 2 · Venetoclax + Rituximab (VenR), 24-month fixed-duration (MURANO schedule)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-VENETOCLAX-RITUXIMAB |
| ID | IND-CLL-2L-VENR-MURANO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-09 | pending_clinical_signoff |
| Diseases | DIS-CLL |
| Sources | SRC-ESMO-CLL-2024 SRC-MURANO-SEYMOUR-2018 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Co-Lead sign-off. Standard-track 2L for r/r CLL — fixed-duration alternative to continued BTKi switch. Particularly valuable when 1L BTKi has progressed (mechanism-of-action switch). Distinct from VenO 1L (IND-CLL-1L-VENO) — different anti-CD20 partner + duration. UA: venetoclax not reimbursed; rituximab reimbursed.
Used By
Algorithms
ALGO-CLL-2L- ALGO-CLL-2L